Mercer Global Advisors
IMDX

Mercer Global Advisors’s Insight Molecular Diagnostics IMDX Stock Holding History

Mercer Global Advisors’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30 Buy
+5
New +$25 ﹤0.01% 6029

Other funds holding IMDX

FOR
Family Office Research Bethesda, Maryland $267M AUM 27.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
AXQ Capital Jersey City, New Jersey $920M AUM 18.71% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.72% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Mercer Global Advisors's IMDX Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Insight Molecular Diagnostics (IMDX) in Q2 2026: 5 shares worth $30. The stake represents ﹤0.01% of the portfolio and ranks #6029 among its holdings.

17 funds tracked by Wall St. Rank hold IMDX as of Q2 2026.

  • Mercer Global Advisors held 5 shares of Insight Molecular Diagnostics worth $30 as of Q2 2026.
  • Insight Molecular Diagnostics was a new Mercer Global Advisors position in Q2 2026.
  • Insight Molecular Diagnostics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #6029 holding.
  • 17 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.